Baseline characteristics | n=140 |
---|---|
Male | 108 (77%) |
Average age and range (years) | 67 (29–89) |
Mean ejection fraction (range) | 23% (8%>35%) |
NYHA 2 | 74 (53%) |
NYHA 3 | 65 (46%) |
NYHA 4 | 1 (1%) |
Comorbidities | |
Ischaemic heart disease | 46 (33%) |
Atrial fibrillation | 53 (38%) |
Diabetes mellitus | 36 (26%) |
Hypertension | 49 (35%) |
CKD | 39 (28%) |
Medication | |
ACE-i | 103 (73%) |
ARB | 38 (27%) |
Beta blocker | 135 (96%) |
MRA | 96 (69%) |
Loop diuretics | 104 (74%) |
All devices | 30 (21%) |
CRT (D/P) | 22 (16%) |
ICD | 8 (6%) |
ACE-i = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CKD = chronic kidney disease; CRT = cardiac resynchronisation therapy; ICD = implantable cardioverter defibrillator; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.